GBG HOME

Peer-reviewed articles in 2020

  • Furlanetto J, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Lübbe K, Untch M et al. Germline BRCA1/2 mutations and severe hematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer. 2021; 145:44-52.
  • Reimer T, Glass A, Botteri E, Loibl S, D Gentilini O. Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial. Cancers (Basel). 2020;12:3698.
  • Kolberg HC, Kühn T, Krajewska M, Bauerfeind I, Fehm TN, Fleige B, et al. Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases - a transSENTINA Analysis. Geburtshilfe Frauenheilkd. 2020;80:1229-1236.
  • André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, et al. Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1. Ann Oncol. 2020; doi: 10.1016/j.annonc.2020.11.011.
  • Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer JU, Zahm DM, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching PA, Untch M, Loibl S, Weber K, Seliger B. Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. J Immunother Cancer. 2020; 8:e001261.
  • Rüger AM, Schneeweiss A, Seiler S, Tesch H, van Mackelenbergh M, Marmé F, et al. Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial. J Am Heart Assoc. 2020;9:e018143.
  • Chan A, Moy B, Mansi J, Ejlertsen B, Holmes FA, Chia S, et al. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. Clin Breast Cancer. 2020; doi: 10.1016/j.clbc.2020.09.014.
  • Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol. 2020; doi: 10.1016/j.annonc.2020.10.471.
  • Guerini-Rocco E, Gray KP, Fumagalli C, Reforgiato MR, Leone I, Rafaniello Raviele P, et al. Genomic aberrations and late recurrence in postmenopausal women with hormone receptor-positive early breast cancer: Results from the SOLE Trial. Clin Cancer Res. 2020; doi: 10.1158/1078-0432.CCR-20-0126.
  • Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon TW, et al. Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. Cancers (Basel). 2020; 12:2787.
  • O'Leary B, Cutts RJ, Huang X, Hrebien S, Liu Y, André F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M, Bartlett CH, Turner NC. Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer. J Natl Cancer Inst. 2020; djaa087.
  • Jank P, Gehlhaar C, Lederer B, Fontanella C, Schneeweiss A, Karn T, et al. MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial. PLoS One. 2020;15:e0238021.
  • Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, et al. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol. 2020;38:2610-2619.
  • Karn T, Denkert C, Weber KE, Holtrich U, Hanusch C, Sinn BV, et al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Ann Oncol. 2020;31:1216-1222.
  • Hildebrandt G, Stachs A, Gerber B, Potenberg J, Krug D, Wolter K, et al. Central Review of Radiation Therapy Planning Among Patients with Breast-Conserving Surgery: Results from a Quality Assurance Process Integrated into the INSEMA Trial. Int J Radiat Oncol Biol Phys. 2020;107:683-693.
  • Rugo HS, André F, Yamashita T, Cerda H, Toledano I, Stemmer SM, et al. Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer. Ann Oncol. 2020;31:1001-1010.
  • Conte P, Schneeweiss A, Loibl S, Mamounas EP, von Minckwitz G, Mano MS, et al. Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. Cancer. 2020;126:3132-3139.
  • Werutsky G, Untch M, Hanusch C, Fasching PA, Blohmer JU, Seiler S, et al. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. Eur J Cancer. 2020;130:92-101.
  • Pohl-Rescigno E, Hauke J, Loibl S, Möbus V, Denkert C, Fasching PA, et al. Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial. JAMA Oncol. 2020;6:744-748.
  • Karn T, Meissner T, Weber K, Solbach C, Denkert C, Engels K, et al. A small hypoxia signature predicted pCR response to bevacizumab in the neoadjuvant GeparQuinto breast cancer trial. Clin Cancer Res. 2020; 26:1896-1904.
  • Guo S, Loibl S, Minckwitz GV, Darb-Esfahani S, Lederer B, Denkert C. PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy. Cancer Res Treat. 2020;52:689-696.
  • Sonnenblick A, Salmon-Divon M, Salgado R, Dvash E, Pondé N, Zahavi T, et al. Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer. Int J Cancer. 2020;147:266-276.
  • Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382:597-609.
  • Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, et al. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer. 2020;6:17.
  • Furlanetto J, Loibl S. Optimal Systemic Treatment for Early Triple-Negative Breast Cancer. Breast Care (Basel). 2020;15:217-226.
  • Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las Heras B, et al. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. Br J Cancer. 2020; 123:694-697.
  • de Azambuja E, Trapani D, Loibl S, Delaloge S, Senkus E, Criscitiello C, et al. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. ESMO Open. 2020;5(Suppl 3):e000793.
  • Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, et al. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. NPJ Breast Cancer. 2020;6:15. Published 2020; 6:15.
  • Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, et al. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2020;6:16.
  • Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, et al. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol. 2020;250:667-684.


News

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd